论文部分内容阅读
目的:观察小牛血清去蛋白注射液(DCBI)对2型糖尿病合并脑梗死模型大鼠血糖、血脂代谢的影响及其对胰岛素抵抗(IR)的改善作用。方法:大鼠用高脂高糖饮食伴尾静脉注射链脲佐菌素复制2型糖尿病模型,成功后再建立大鼠大脑中动脉栓塞模型,分为模型组、假手术组、DCBI(低、高剂量,30、60mg·kg-1·d-1,腹腔注射)组和对照药罗格列酮组;并设立正常组。各组给予相应试药5周后,测定空腹血糖(FBG)、血清胰岛素(FI NS)、糖耐量(OGTT)水平,并计算胰岛素抵抗指数(IRI)、胰岛素敏感指数(ISI),测定总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、游离脂肪酸(NEFA)水平。结果:与模型组比较,DCBI治疗后可显著降低2型糖尿病合并脑梗死模型大鼠FBG水平及增强糖耐量(P<0.01),对FI NS水平的改变不明显(P>0.05);改善机体对胰岛素的抵抗性(P<0.01或P<0.05);并明显降低TC、TG、LDL-C、NEFA水平及升高HDL-C水平(P<0.01),改善高脂状态。结论:DCBI可降低2型糖尿病合并脑梗死模型大鼠血糖,调节血脂代谢紊乱,具有改善IR的作用。
Objective: To observe the effects of deproteinizing calf serum (DCBI) on blood glucose and lipid metabolism in type 2 diabetic rats with cerebral infarction and its effect on improving insulin resistance (IR). Methods: Rats with type 2 diabetes mellitus were injected with streptozotocin (STZ) through the tail vein of a high-fat and high-sugar diet. After successful, the rat model of middle cerebral artery occlusion was established and divided into model group, sham operation group, DCBI (low, High-dose, 30,60 mg · kg-1 · d-1, intraperitoneal injection) and control group rosiglitazone group; and set up a normal group. After 5 weeks, the fasting blood glucose (FBG), insulin (FI NS) and glucose tolerance (OGTT) were measured and the insulin resistance index (IRI) and insulin sensitivity index (ISI) TC, TG, HDL-C, LDL-C and NEFA were measured. Results: Compared with the model group, DCBI treatment significantly reduced the level of FBG and glucose tolerance (P <0.01), but did not change the level of FI NS in type 2 diabetic rats with cerebral infarction (P> 0.05) Insulin resistance (P <0.01 or P <0.05). The levels of TC, TG, LDL-C, NEFA and HDL-C were also significantly decreased (P <0.01) Conclusion: DCBI can reduce blood glucose in type 2 diabetic rats with cerebral infarction, regulate dyslipidemia and improve IR.